In this webinar, we will explore the numerous advantages blow-fill-seal (BFS) unidose format offer over multidose options for ocular applications, as well as over single-dose glass vials. We will dive into the aspects pharma and biotech companies need to consider to utilise BFS in ophthalmic drug development and outline how a CDMO can support making the most of this technology.
Webinar learning objectives
- What is BFS technology and the unique benefits of unidose BFS for ophthalmics, biologics and other sterile drug products
- What are the advantages of BFS unidose format in comparison to ocular multidose or glass vial format?
- How Recipharm can support companies in switching to unidose BFS
Our speakers
Jean-Christophe Moreau, Technical Transfer Director
As Technical Transfer Director at Recipharm, Kaysersberg site (France), Jean-Christophe Moreau leads the team responsible for introducing new BFS products on site. He is a pharmacist with 29 years’ experience within the pharma industry across several companies, technologies (sterile and non-sterile), positions and countries.
Yves Buelens, Plant Manager
Yves Buelens is General Manager at Recipharm, Kaysersberg (France) site, and is an industrial pharmacist with 30 years’ experience in the pharmaceutical industry, working with various technologies (sterile and non-sterile). Yves previously worked with several big pharma companies (Upjohn, Schering-Plough, J&J, Alcon/Novartis) and CDMOs (Nextpharma, Catalent) environment.
Christophe Schwoehrer, Manufacturing Science & Technology Aseptic Filling Expert
Christophe Schwoehrer is a manufacturing science and technology aseptic filling expert at the Recipharm Kaysersberg (France) site. In 2022, he gained the role of Chairman of the Pharmaceutical Blow-Fill-Seal International Operators Association (BFDS IOA). Christophe has 32 years’ experience in maintenance and project management within the pharma industry.